Cargando…
Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma
We conducted a prospective, three-center, observational study in Japan to evaluate the prevalence of seropositivity and clinically protective titer after coronavirus disease 2019 vaccination in patients with plasma cell dyscrasia(PCD). Two-hundred sixty-nine patients with PCD [206 symptomatic multip...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860256/ https://www.ncbi.nlm.nih.gov/pubmed/35190963 http://dx.doi.org/10.1007/s12185-022-03300-4 |
_version_ | 1784654631183319040 |
---|---|
author | Terao, Toshiki Yamashita, Takeshi Fukumoto, Ami Kamura, Yuya Ikeda, Daisuke Kuzume, Ayumi Tabata, Rikako Tsushima, Takafumi Miura, Daisuke Narita, Kentaro Takeuchi, Masami Doi, Masahiro Umezawa, Yuka Otsuka, Yoshihito Takamatsu, Hiroyuki Matsue, Kosei |
author_facet | Terao, Toshiki Yamashita, Takeshi Fukumoto, Ami Kamura, Yuya Ikeda, Daisuke Kuzume, Ayumi Tabata, Rikako Tsushima, Takafumi Miura, Daisuke Narita, Kentaro Takeuchi, Masami Doi, Masahiro Umezawa, Yuka Otsuka, Yoshihito Takamatsu, Hiroyuki Matsue, Kosei |
author_sort | Terao, Toshiki |
collection | PubMed |
description | We conducted a prospective, three-center, observational study in Japan to evaluate the prevalence of seropositivity and clinically protective titer after coronavirus disease 2019 vaccination in patients with plasma cell dyscrasia(PCD). Two-hundred sixty-nine patients with PCD [206 symptomatic multiple myeloma (MM)] were evaluated. Seropositivity was observed in 88.7% and a clinically protective titer in 38.3% of MM patients, both of which were significantly lower than those of healthy controls. Patients receiving anti-CD38 antibodies had much lower antibody titers, but antibody titers recovered in those who underwent a wash-out period before vaccine administration. Older age (≥65), anti-CD38 antibody administration, immunomodulatory drugs use, lymphopenia (<1000/μL), and lower polyclonal IgG (<550 mg/dL) had a negative impact for the sufficient antibody production according to multivariate analysis. Patients with clinically protective titer had a significantly higher number of CD19+ lymphocytes than those with lower antibody responses (114 vs. 35/μL, p = 0.016). Our results suggested that patients with PCD should be vaccinated, and that the ideal protocol is to temporarily interrupt anti-CD38 antibody therapy for a “wash-out” period of a few months, followed by a (booster) vaccine after the B-cells have recovery. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12185-022-03300-4. |
format | Online Article Text |
id | pubmed-8860256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-88602562022-02-22 Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma Terao, Toshiki Yamashita, Takeshi Fukumoto, Ami Kamura, Yuya Ikeda, Daisuke Kuzume, Ayumi Tabata, Rikako Tsushima, Takafumi Miura, Daisuke Narita, Kentaro Takeuchi, Masami Doi, Masahiro Umezawa, Yuka Otsuka, Yoshihito Takamatsu, Hiroyuki Matsue, Kosei Int J Hematol Original Article We conducted a prospective, three-center, observational study in Japan to evaluate the prevalence of seropositivity and clinically protective titer after coronavirus disease 2019 vaccination in patients with plasma cell dyscrasia(PCD). Two-hundred sixty-nine patients with PCD [206 symptomatic multiple myeloma (MM)] were evaluated. Seropositivity was observed in 88.7% and a clinically protective titer in 38.3% of MM patients, both of which were significantly lower than those of healthy controls. Patients receiving anti-CD38 antibodies had much lower antibody titers, but antibody titers recovered in those who underwent a wash-out period before vaccine administration. Older age (≥65), anti-CD38 antibody administration, immunomodulatory drugs use, lymphopenia (<1000/μL), and lower polyclonal IgG (<550 mg/dL) had a negative impact for the sufficient antibody production according to multivariate analysis. Patients with clinically protective titer had a significantly higher number of CD19+ lymphocytes than those with lower antibody responses (114 vs. 35/μL, p = 0.016). Our results suggested that patients with PCD should be vaccinated, and that the ideal protocol is to temporarily interrupt anti-CD38 antibody therapy for a “wash-out” period of a few months, followed by a (booster) vaccine after the B-cells have recovery. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12185-022-03300-4. Springer Nature Singapore 2022-02-21 2022 /pmc/articles/PMC8860256/ /pubmed/35190963 http://dx.doi.org/10.1007/s12185-022-03300-4 Text en © Japanese Society of Hematology 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Article Terao, Toshiki Yamashita, Takeshi Fukumoto, Ami Kamura, Yuya Ikeda, Daisuke Kuzume, Ayumi Tabata, Rikako Tsushima, Takafumi Miura, Daisuke Narita, Kentaro Takeuchi, Masami Doi, Masahiro Umezawa, Yuka Otsuka, Yoshihito Takamatsu, Hiroyuki Matsue, Kosei Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma |
title | Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma |
title_full | Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma |
title_fullStr | Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma |
title_full_unstemmed | Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma |
title_short | Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma |
title_sort | low clinical protective response to sars-cov-2 mrna covid-19 vaccine in patients with multiple myeloma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860256/ https://www.ncbi.nlm.nih.gov/pubmed/35190963 http://dx.doi.org/10.1007/s12185-022-03300-4 |
work_keys_str_mv | AT teraotoshiki lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma AT yamashitatakeshi lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma AT fukumotoami lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma AT kamurayuya lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma AT ikedadaisuke lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma AT kuzumeayumi lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma AT tabatarikako lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma AT tsushimatakafumi lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma AT miuradaisuke lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma AT naritakentaro lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma AT takeuchimasami lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma AT doimasahiro lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma AT umezawayuka lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma AT otsukayoshihito lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma AT takamatsuhiroyuki lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma AT matsuekosei lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma |